Dow Up0.51% Nasdaq Up0.24%

Seattle Genetics Inc. (SGEN)

36.85 Up 0.25(0.68%) Nov 21, 4:00PM EST
|After Hours : 36.85 0.00 (0.00%) Nov 21, 5:00PM EST
ProfileGet Profile for:
Seattle Genetics Inc.
21823 30th Drive SE
Bothell, WA 98021
United States - Map
Phone: 425-527-4000
Fax: 425-527-4001

Index Membership:N/A
Full Time Employees:582

Business Summary 

Seattle Genetics, Inc., a biotechnology company, develops and commercializes antibody-based therapies for the treatment of cancer. The company is developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Its lead product, ADCETRIS (brentuximab vedotin), is an ADC that has been approved in approximately 35 countries, including the United States, Canada, Japan, and members of the European Union for relapsed Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL) in collaboration with Takeda Pharmaceutical Company Limited. The company also evaluates approximately 30 ongoing clinical trials, including Phase III trials for post-transplant HL relapse prevention, relapsed CD30-positive cutaneous T-cell lymphoma, frontline HL in combination with chemotherapy, and frontline CD30-positive mature T-cell lymphoma in combination with chemotherapy, as well as in Phase I and II studies in various lymphoma and non-lymphoma indications. In addition, it is developing a pipeline of other clinical-stage ADC programs, including SGN-CD19A for CD19A-positive hematologic malignancies, SGN-CD33A in CD33-positive acute myeloid leukemia, SGN-LIV1A in LIV-1-positive breast cancer, ASG-22ME for treatment of Nectin-4-positive solid tumors, and ASG-15ME for treatment of SLITRK6-positive bladder cancer. The company has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie, Agensys, Bayer, Genentech, GlaxoSmithKline, and Pfizer. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Seattle Genetics Inc.

Corporate Governance 
Seattle Genetics Inc.’s ISS Governance QuickScore as of Nov 1, 2014 is 7. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 7; Compensation: 8.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. Clay B. Siegall Ph.D., 53
Co-Founder, Chairman, Chief Exec. Officer and Pres
Mr. Todd E. Simpson , 53
Chief Financial Officer and Principal Accounting Officer
Mr. Eric L. Dobmeier J.D., 45
Chief Operating Officer and Corp. Sec.
Dr. Jonathan Drachman M.D., 52
Chief Medical Officer and Exec. VP of R&D
Dr. Vaughn B. Himes Ph.D., 53
Exec. VP of Technical Operations & Process Sciences
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders